Contents 4 dk okuma
Important Note
This page is not medical advice. Phenylpiracetam has strong stimulant effects; Tolerance develops rapidly. Individuals with heart disease, hypertension or psychiatric disorders should not use it. Consult a healthcare professional.
What is Phenylpiracetam?
Phenylpiracetam is a synthetic racetam compound derived by adding the phenyl group of piracetam. It was developed in 1983 by researchers of the Russian Academy of Sciences to protect the cognitive performance of Soviet cosmonauts under stress, fatigue and extreme conditions within the scope of the space program.
It is sold as a prescription drug under the brand name "Phenotropil" in Russia; It is used in the treatment of cerebral circulation disorders, depression and sleep disorders. WADA (World Anti-Doping Agency) has kept phenylpiracetan (under the name fonturacetam / carphedone) in the stimulants class on the list of banned substances since 1998 due to its performance-enhancing effect; This is considered an independent indicator of the compound's effect on performance.
Mechanism of Effect
Phenylpiracetam, in addition to the AMPA receptor modulation it shares with piracetam, carries much more pronounced monoaminergic effects resulting from its phenyl group. The combination of these two layers of effects accounts for both the cognitive and physical/stimulatory benefits.
AMPA receptor positive allosteric modulation: Like Piracetam, it strengthens AMPA type glutamate receptors; This effect increases memory consolidation and learning capacity. Phenylpiracetam achieves this effect at a much lower dose (approximately 20–60 times more potent) than piracetam.
Dopamine and noradrenaline reuptake inhibition: The phenyl group enables the compound to interact with monoamine transporters (DAT, NET). Inhibition of dopamine and noradrenaline reuptake explains the marked increase in arousal, motivation, focus and physical energy.
Nicotine acetylcholine receptor modulation: It is reported to increase the density of alpha-4-beta-2 nicotinic receptors; This effect makes an additional contribution to cognitive speed and attention.
| mechanism | Impact | Piracetam Difference |
|---|---|---|
| AMPA positive modulation | Memory consolidation, learning increase | Similar, more potent |
| DAT/NET inhibition | Arousal, motivation, energy | Not in Piracetam |
| Nicotinic receptor increase | Cognitive speed and attention | Not in Piracetam |
| Increased cold tolerance | Physiological resistance to cold | Not in Piracetam |
Clinical Evidence
The majority of phenylpiracetam research has been conducted in Russia and published in Russian; This situation creates difficulty in evaluation in western sources.
Malykh and Sadaie (2010) In the comprehensive review published by , the pharmacological profiles of various racetam compounds, including phenylpiracetan, were compared; It was summarized that phenylpiracetan showed significant superiority in terms of both cognitive and stimulant effects compared to standard piracetam.
Russian clinical studies reported positive results on neurological function recovery, depression and anxiety reduction, and resistance to cognitive fatigue after cerebral ischemia. However, the majority of these studies have not been evaluated according to Western standards of methodology.
⚠ Tolerance and Limited Evidence Warning
The most critical limitation of phenylpiracetam is the rapid development of tolerance; With daily use, the stimulating effects begin to decrease within 2–4 days. It is recommended to use 2-3 times a week at most. International Western RCT evidence is quite limited; effectiveness is largely based on Russian clinical literature.
Dosage Protocol
Phenylpiracetam should not be taken in the afternoon or evening due to its strong stimulant effect; may cause sleep disturbance.
| Intended Use | Dose | Timing and Cycle |
|---|---|---|
| First use (test dose) | 50–100 mg | Early morning; tolerance assessment |
| Standard cognitive/energy support | 100–200 mg | Morning; per week max. 2–3 days |
| Clinical study dose | 100–200 mg × 2/day | Under the supervision of a doctor; short term |
Tolerance management: For minimum effect, take a break for at least 2 days. A weekly usage cycle (e.g. Monday-Wednesday-Friday) minimizes tolerance. Continuous daily use leads to rapid deactivation.
Safety and Side Effects
- Sleep disorder: It is almost inevitable when taken in the afternoon; Use only in the morning.
- Heart palpitations (palpitations): Due to monoaminergic effect; Do not use in heart patients.
- Anxiety/irritability: Possible at high doses or when combined with caffeine.
- Appetite suppression: It is especially evident in the first hours due to the dopaminergic effect.
- Collapse effect (crash): Fatigue and loss of motivation when the effect wears off; The risk increases with frequent use.
Who Does It Interact With?
- Caffeine: Synergistic stimulating effect; If taken together, the dose should be reduced.
- MAO inhibitors: Potential risk of serotonin syndrome; Never combine.
- Piracetam and other racetams: The effects overlap; Concomitant use is generally unnecessary.
- Stimulant drugs (Ritalin, Adderall): Potential for serious interaction; Avoid combining.
Sources
- Malykh AG & Sadaie MR (2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs, 70(3), 287–312. PubMed · PMID 20166767
- Zvejniece L, et al. (2011). Investigation into stereoselective pharmacological activity of phenotropil. Basic & Clinical Pharmacology & Toxicology, 109(5), 407–412. PubMed · PMID 21689376
- Akhapkina VI & Akhapkin RV (2002). Effects of phenotropil on cognitive function and quality of life in patients with consequences of stroke and traumatic brain injury. Zhurnal Nevrologii i Psikhiatrii imeni Korsakova, 102, 45–48. Search PubMed (match unverified)
- Firstova YY, et al. (2011). Studying specific nootropic activity of the peptide preparation noopept and phenotropil on a model of scopolamine-induced cognitive deficit in rats. Eksperimentalnaya i Klinicheskaya Farmakologiya, 74(4), 3–7. Search PubMed (match unverified)
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Phenylpiracetam is a racetam compound that improves both cognitive and physical performance. It supports memory consolidation while strengthening focus, energy and motivation. It was originally developed in the Russian space program to maintain the mental performance of cosmonauts under stress and fatigue.
For beginners, it is recommended to start with 50-100 mg; The standard dose for experienced users is between 100-200 mg. Due to its strong stimulant effect, it should be taken early in the morning; Taking it in the afternoon or evening causes sleep disturbance. It should be used no more than 2-3 times a week to prevent the development of tolerance.
The most common side effects are: sleep disturbance (when taken in the afternoon), heart palpitations, anxiety and irritability (especially when combined with caffeine), appetite suppression and feeling tired after the effect wears off. People with heart disease, hypertension or psychiatric disorders should not use it.
Phenylpiracetam is not an approved or licensed drug in Türkiye and is not sold in pharmacies. It is available as a prescription drug in Russia under the name Phenotropil. It has been included in the stimulant class on the list of banned substances by WADA since 1998 (under the name fonturacetam/carfedon). Imports in Türkiye are in a gray area and it is recommended to evaluate the legal situation before using any foreign sources.
Phenylpiracetam usually begins to work 30-60 minutes after taking it. The peak of effect is reached in approximately 1-2 hours and the total duration of effect is between 4-6 hours. Due to rapid tolerance development, stimulant effects decrease significantly within 2-4 days of daily use; so intermittent use is essential.
